Demystifying Asia: Best Practices for Conducting Multinational Clinical TrialsWith an increasing need for biopharma companies to bring more products to market faster, there is growing interest in accessing multinational patient populations to speed enrollment.

However, historically, some sponsors and CROs have been hesitant to consider Asia to enroll patients in their multinational clinical trials. If they go to Asia, can be they be successful? Can they be guaranteed comparable training and GCP compliance?

Yet Asian countries have proven to be an exciting and rapidly growing region in which to conduct trials, ripe with opportunities and access to significant patient populations, availability of treatment naïve patients and Western patterns of illness and treatment. In fact, the biggest perceived advantage is the availability of patients: Asia, as a whole, represents 60% of the world’s population.

Download this eBook to learn:

  • Why oncology trials are a particularly appropriate area of research to conduct in Asia
  • Best practices you can apply to enrolling patients in Asia
  • Challenges and opportunities across the region, including China, Singapore, South Korea, Taiwan, Japan, and Vietnam.

If you’re interested in more information about conducting multinational clinical trials in Asia, please click here to watch a recorded webcast.

Back to Blog